The global overactive bladder (OAB) therapeutics market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). The major factor that is expected to boost the market growth includes an rising incidences of overactive bladder disorder coupled with an aging population. Moreover, manufacturers are continuously increasing their R&D expenditure to develop novel drugs such as neuromuscular blocking agents with innovative mechanisms of action, which in turn is expected to fuel the growth of the global overactive bladder (OAB) therapeutics market. In addition, the development of innovative intravesical therapies are further driving the growth of the market. 

Therapy approvals are regulated by various regional regulatory authorities. The changing regulatory scenario favoring overactive bladder treatments in a number of countries, such as UK and Japan, will offer significant growth opportunities for market players. For instance, the UK’s National Institutes for Health and Care Excellence (NICE) reimburses the BOTOX therapy. In 2007, the Japanese Ministry of Health, Labour and Welfare (MHLW) launched an action plan to promote the safe use of generics. Overactive bladder is a medical syndrome, defined by urinary incontinence usually characterized by high urine frequency or nocturia. The common symptoms of OAB include urgency, high urinary frequency, and urge incontinence. Anticholinergic agents are considered the first-line treatment for overactive bladder disorders. Flavoxate, oxybutynin, tolterodine are some of the generic drugs used for the treatment of overactive bladder. These drugs act by antagonizing cholinergic receptors that provide relief from frequent urination.

Market Coverage

• The market number available for – 2020-2027

• Base year- 2020

• Forecast period- 2021-2027

• Segment Covered- 

o By Type 

o By Application 

• Regions covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape: Allergan plc, Astellas Pharma Inc., and Teva Pharmaceutical Industries Ltd., among others.

Key questions addressed by the report

• What is the market growth rate?

• Which segment and region dominate the market in the base year?

• Which segment and region will project the fastest growth in the market?

• How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?

• How are players addressing challenges to sustain growth?

• Where is the investment opportunity?

Global Overactive Bladder (OAB) Therapeutics Market Report by Segment

By Type

• Anticholinergic Agents

• Beta-3 Adrenoreceptor Agonists

By Application

• Hospitals

• Clinics

• Others

Global Overactive Bladder (OAB) Therapeutics Market Report by Region

North America       

• US

• Canada

Europe

• Germany

• UK

• France

• Spain

• Italy

• Rest of Europe

Asia-Pacific    

• China

• Japan

• India

• Rest of Asia-Pacific

Rest of the World

• Latin America

• Middle East and Africa